Caffeine pharmacokinetics during hyperbaric hyperoxia in humans

Aviation Space and Environmental Medicine

Volumn 68, Issue 2, 1997, Pages 142-146

  Rump, A F E ^a   Siekmann, U ^a   Dreja, M ^b   Kalff, G ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Institute for Hyperbaric Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COFFEE; DECOMPRESSION SICKNESS; DIVING; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; HYPERBARISM; HYPOXIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

ADULT; BIOLOGICAL AVAILABILITY; CAFFEINE; DRUG MONITORING; HUMANS; HYPERBARIC OXYGENATION; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0031030577     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ananian AA, Miliutina WP, Shugalei VS, Sherstner KB, Kostkin VB. The cytochrome P-450 content and catalytic activity in rat liver microsomes during hyperbaric oxygenation. Biol Nauki 1991; 12:28-33.
2. Balogh A, Vollandt R. Intra-individual variability of caffeine elimination in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 1992; 345 (Suppl):R1.
3. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983; 24:93-8.
4. Boehm F, Almeling M. Überlegungen zum Einsatz von Acetylsalicylsäure bei Tauchunfall. Notarzt 1995; 11:9-12.
5. Broughton LJ, Rogers HJ. Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol 1981; 12:155-9.
6. Derendorf H, Garrett ER. Pharmacokinetik. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1987.
7. Edmonds C, Lowry C, Pennefather J. Diving and subaquatic medicine. Oxford: Butterworth Heinemann, 1992.
8. Fischer B, Jain KK, Braun E, Lehri S. Handbook of hyperbaric oxygen therapy. Berlin: Springer, 1988.
9. Gleiter CH, Deckert J. Coffein. Klinische Pharmakologie und Anwendung als Pharmakon. Arzneimitteltherapie 1992; 10(8):244-55.
10. Gooden BA. Mechanism of the human diving response. Integr Physiol Behav Sci 1994; 29:6-16.
11. Holzapfel R. Praxis der Tauchmedizin. Stuttgart: Thieme, 1993.
12. Hull CJ. Pharmacokinetics for Anaesthesia. Oxford: Butterworth Heinemann, 1991.
13. Knobelsdorff G v. Druckluft-und Tauchunfälle im Rettungsdienst. Notarzt 1993; 9:142-6.
14. Kramer WG, Gross DR, Fife WP, Chaikin BN. Theophylline pharmacokinetics during hyperbaria and hyperbaric hyperoxia in the dog. Res Comm Chem Pathol Pharmacol 1981; 34(3):381-8.
15. Kramer WG, Gross DR, Moreau PM, Fife WP. Drug disposition under hyperbaric and hyperbaric hyperoxic conditions: Meperidine in the dog. Aviat Space Environ Med 1983; 54(5):410-2.
16. Kramer WG, Welch DW, Fife WP, Chaikin BN, Gross DR. Salicylate pharmacokinetics in the dog at 6 ata in air and at 2.8 ata in 100% oxygen. Aviat Space Environ Med 1983; 54(8):682-4.
17. Kramer WG, Welch DW, Fife WP, et al. Pharmacokinetics of pentobarbital under hyperbaric and hyperbaric hyperoxic conditions in the dog. Aviat Space Environ Med 1983; 54(11):1005-8.
18. Merritt GJ, Slade JB. The influence of hyperbaric oxygen on the pharmacokinetics of single dose gentamycin in healthy volunteers. Pharmacotherapy 1993; 13(4):382-5.
19. Risberg J, Bergo GW, Hordnes C, Tyssebotn I. Distribution of cardiac output in awake rats during exposure to 5 bar. Undersea Biomed Res 1990; 17(6):503-14.
20. Risberg J, Hordnes C, Stuhr LEB, Tyssebotn I. Effect of β1-adrenoceptor blockade in rats at 5 bar ambient pressure. Undersea Hyperbaric Med 1994; 21(4):371-85.
21. Stegemann J. Leistungsphysiologie. Stuttgart: Thieme, 1991.
22. Walsh JM. Behavioral effects of drugs in the hyperbaric environment. In: Walsh JM, ed. Interaction of drugs in the hyperbaric environment. U.M.S. Publication Number 21(DR) 10-1-80. Bethesda: Undersea Medical Society, 1980: 17-21.
23. Weiss NA, Hassett MJ. Introductory statistics. Reading: Addison-Wesley Publishing Company, 1987.